Eupraxia Pharmaceuticals (EPRX) Convertible Debt (2022 - 2024)

Eupraxia Pharmaceuticals (EPRX) has 3 years of Convertible Debt data on file, last reported at $4.5 million in Q2 2024.

• On a quarterly basis, Convertible Debt changed N/A year-over-year to $4.5 million in Q2 2024; TTM through Jun 2024 was $4.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $10.3 million, up 18.23% from the prior year.
• Convertible Debt for Q2 2024 stood at $4.5 million, down from $9.5 million in the prior quarter.
• Over the last five years, Convertible Debt for EPRX reached as high as $10.3 million in Q4 2023 and fell as low as $4.5 million in Q2 2024.
• Historically, Convertible Debt has averaged $8.3 million across 3 years, with a median of $9.1 million in 2022.
• On a YoY basis, Convertible Debt climbed as much as 18.23% in 2023 and fell as far as 18.23% in 2023.
• Year by year, Convertible Debt stood at $8.7 million in 2022, then grew by 18.23% to $10.3 million in 2023, then tumbled by 56.15% to $4.5 million in 2024.
• Per Business Quant data, the three most recent Convertible Debt figures were $4.5 million in Q2 2024, $9.5 million in Q1 2024, and $10.3 million in Q4 2023.